<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lobato CB</submitter><funding>Fundação para a Ciência e a Tecnologia</funding><funding>Novo Nordisk Foundation Center for Basic Metabolic Research</funding><pagination>608248</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7793799</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11</volume><pubmed_abstract>Obesity and obesity-related diseases are major public health concerns that have been exponentially growing in the last decades. Bariatric surgery is an effective long-term treatment to achieve weight loss and obesity comorbidity remission. Post-bariatric hypoglycemia (PBH) is a late complication of bariatric surgery most commonly reported after Roux-en-Y gastric bypass (RYGB). PBH is the end result of postprandial hyperinsulinemia but additional endocrine mechanisms involved are still under debate. Our aim was to characterize entero-pancreatic hormone dynamics associated with postprandial hypoglycemia after RYGB. Individuals previously submitted to RYGB (&lt;i>N&lt;/i>=23) in a single tertiary hospital presenting PBH symptoms (&lt;i>Sym&lt;/i>, &lt;i>n&lt;/i>=14) and asymptomatic weight-matched controls (&lt;i>Asy&lt;/i>, &lt;i>n&lt;/i>=9) were enrolled. Participants underwent a mixed-meal tolerance test (MMTT) to assess glucose, total amino acids (total AA), insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and neurotensin (NT). We found that hypoglycemia during the MMTT was equally frequent in &lt;i>Sym&lt;/i> and &lt;i>Asy&lt;/i> groups (&lt;i>p&lt;/i>=1.000). Re-grouped according to glucose nadir during the MMTT (&lt;i>Hypo&lt;/i> &lt;i>n&lt;/i>=11 vs &lt;i>NoHypo&lt;/i> &lt;i>n&lt;/i>=12; nadir &lt;3.05 mmol/l vs ≥3.05 mmol/l), subjects presented no differences in anthropometric (BMI: &lt;i>p&lt;/i>=0.527) or metabolic features (HbA&lt;sub>1c&lt;/sub>: &lt;i>p&lt;/i>=0.358), yet distinct meal-elicited hormone dynamics were identified. Postprandial glucose excursion and peak glucose levels were similar (&lt;i>p&lt;/i>>0.05), despite distinct late glycemic outcomes (t=60 min and t=90 min: &lt;i>p&lt;/i>&lt;0.01), with overall greater glycemic variability in &lt;i>Hypo&lt;/i> group (minimum-to-maximum glucose ratio: &lt;i>p&lt;/i>&lt;0.001). &lt;i>Hypo&lt;/i> group meal-triggered hormone profile was characterized by lower early glucagon (t=15 min: &lt;i>p&lt;/i>&lt;0.01) and higher insulin (t=30 min: &lt;i>p&lt;/i>&lt;0.05, t=45 min: &lt;i>p&lt;/i>&lt;0.001), C-peptide (t=30 min: &lt;i>p&lt;/i>&lt;0.01, t=45 min: &lt;i>p&lt;/i>&lt;0.001, t=60 min: &lt;i>p&lt;/i>&lt;0.05), and GLP-1 (t=45 min: &lt;i>p&lt;/i>&lt;0.05) levels. Hyperinsulinemia was an independent risk factor for hypoglycemia (&lt;i>p&lt;/i>&lt;0.05). After adjusting for hyperinsulinemia, early glucagon correlated with glycemic nadir (&lt;i>p&lt;/i>&lt;0.01), and prevented postprandial hypoglycemia (&lt;i>p&lt;/i>&lt;0.05). A higher insulin to glucagon balance in &lt;i>Hypo&lt;/i> was observed (&lt;i>p&lt;/i>&lt;0.05). No differences were observed in total AA, GIP or NT excursions (&lt;i>p&lt;/i>>0.05). In sum, after RYGB, postprandial hyperinsulinemia is key in triggering PBH, but a parallel and earlier rise in endogenous glucagon might sustain the inter-individual variability in glycemic outcome beyond the effect of hyperinsulinism, advocating a potential pivotal role for glucagon in preventing hyperinsulinemic hypoglycemia.</pubmed_abstract><journal>Frontiers in endocrinology</journal><pubmed_title>A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia.</pubmed_title><pmcid>PMC7793799</pmcid><funding_grant_id>UID/MULTI/0215/2016, UID/Multi/00215/2019, UIDB/00215/2020, UIDP/00215/2020</funding_grant_id><pubmed_authors>Guimaraes M</pubmed_authors><pubmed_authors>Lobato CB</pubmed_authors><pubmed_authors>Wewer Albrechtsen NJ</pubmed_authors><pubmed_authors>Nora M</pubmed_authors><pubmed_authors>Holst JJ</pubmed_authors><pubmed_authors>Monteiro MP</pubmed_authors><pubmed_authors>Hartmann B</pubmed_authors><pubmed_authors>Hilsted L</pubmed_authors><pubmed_authors>Pereira SS</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia.</name><description>Obesity and obesity-related diseases are major public health concerns that have been exponentially growing in the last decades. Bariatric surgery is an effective long-term treatment to achieve weight loss and obesity comorbidity remission. Post-bariatric hypoglycemia (PBH) is a late complication of bariatric surgery most commonly reported after Roux-en-Y gastric bypass (RYGB). PBH is the end result of postprandial hyperinsulinemia but additional endocrine mechanisms involved are still under debate. Our aim was to characterize entero-pancreatic hormone dynamics associated with postprandial hypoglycemia after RYGB. Individuals previously submitted to RYGB (&lt;i>N&lt;/i>=23) in a single tertiary hospital presenting PBH symptoms (&lt;i>Sym&lt;/i>, &lt;i>n&lt;/i>=14) and asymptomatic weight-matched controls (&lt;i>Asy&lt;/i>, &lt;i>n&lt;/i>=9) were enrolled. Participants underwent a mixed-meal tolerance test (MMTT) to assess glucose, total amino acids (total AA), insulin, C-peptide, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and neurotensin (NT). We found that hypoglycemia during the MMTT was equally frequent in &lt;i>Sym&lt;/i> and &lt;i>Asy&lt;/i> groups (&lt;i>p&lt;/i>=1.000). Re-grouped according to glucose nadir during the MMTT (&lt;i>Hypo&lt;/i> &lt;i>n&lt;/i>=11 vs &lt;i>NoHypo&lt;/i> &lt;i>n&lt;/i>=12; nadir &lt;3.05 mmol/l vs ≥3.05 mmol/l), subjects presented no differences in anthropometric (BMI: &lt;i>p&lt;/i>=0.527) or metabolic features (HbA&lt;sub>1c&lt;/sub>: &lt;i>p&lt;/i>=0.358), yet distinct meal-elicited hormone dynamics were identified. Postprandial glucose excursion and peak glucose levels were similar (&lt;i>p&lt;/i>>0.05), despite distinct late glycemic outcomes (t=60 min and t=90 min: &lt;i>p&lt;/i>&lt;0.01), with overall greater glycemic variability in &lt;i>Hypo&lt;/i> group (minimum-to-maximum glucose ratio: &lt;i>p&lt;/i>&lt;0.001). &lt;i>Hypo&lt;/i> group meal-triggered hormone profile was characterized by lower early glucagon (t=15 min: &lt;i>p&lt;/i>&lt;0.01) and higher insulin (t=30 min: &lt;i>p&lt;/i>&lt;0.05, t=45 min: &lt;i>p&lt;/i>&lt;0.001), C-peptide (t=30 min: &lt;i>p&lt;/i>&lt;0.01, t=45 min: &lt;i>p&lt;/i>&lt;0.001, t=60 min: &lt;i>p&lt;/i>&lt;0.05), and GLP-1 (t=45 min: &lt;i>p&lt;/i>&lt;0.05) levels. Hyperinsulinemia was an independent risk factor for hypoglycemia (&lt;i>p&lt;/i>&lt;0.05). After adjusting for hyperinsulinemia, early glucagon correlated with glycemic nadir (&lt;i>p&lt;/i>&lt;0.01), and prevented postprandial hypoglycemia (&lt;i>p&lt;/i>&lt;0.05). A higher insulin to glucagon balance in &lt;i>Hypo&lt;/i> was observed (&lt;i>p&lt;/i>&lt;0.05). No differences were observed in total AA, GIP or NT excursions (&lt;i>p&lt;/i>>0.05). In sum, after RYGB, postprandial hyperinsulinemia is key in triggering PBH, but a parallel and earlier rise in endogenous glucagon might sustain the inter-individual variability in glycemic outcome beyond the effect of hyperinsulinism, advocating a potential pivotal role for glucagon in preventing hyperinsulinemic hypoglycemia.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-04-25T20:42:56.016Z</modification><creation>2025-04-06T08:29:20.901Z</creation></dates><accession>S-EPMC7793799</accession><cross_references><pubmed>33424773</pubmed><doi>10.3389/fendo.2020.608248</doi></cross_references></HashMap>